» Articles » PMID: 20393555

Genome Remodelling in a Basal-like Breast Cancer Metastasis and Xenograft

Abstract

Massively parallel DNA sequencing technologies provide an unprecedented ability to screen entire genomes for genetic changes associated with tumour progression. Here we describe the genomic analyses of four DNA samples from an African-American patient with basal-like breast cancer: peripheral blood, the primary tumour, a brain metastasis and a xenograft derived from the primary tumour. The metastasis contained two de novo mutations and a large deletion not present in the primary tumour, and was significantly enriched for 20 shared mutations. The xenograft retained all primary tumour mutations and displayed a mutation enrichment pattern that resembled the metastasis. Two overlapping large deletions, encompassing CTNNA1, were present in all three tumour samples. The differential mutation frequencies and structural variation patterns in metastasis and xenograft compared with the primary tumour indicate that secondary tumours may arise from a minority of cells within the primary tumour.

Citing Articles

Exploration of the clonal evolution and construction of the tumor clonal evolution rate as a prognostic indicator in metastatic breast cancer.

Lv D, Lan B, Guo Q, Yi Z, Qian H, Guan Y BMC Med. 2025; 23(1):122.

PMID: 40001125 PMC: 11863457. DOI: 10.1186/s12916-025-03959-6.


Extracellular vesicle-mediated gene therapy targets BRAF-mutant colorectal cancer by inhibiting the MEK1/2-ERK1/2 pathway.

Wang D, Wang L, Zhang W, Xu K, Chen L, Guo Z J Nanobiotechnology. 2025; 23(1):129.

PMID: 39979881 PMC: 11843959. DOI: 10.1186/s12951-025-03205-4.


Patient-Derived Xenografts of Breast Cancer.

Marangoni E Adv Exp Med Biol. 2025; 1464():109-121.

PMID: 39821023 DOI: 10.1007/978-3-031-70875-6_7.


Modeling Drug Responses and Evolutionary Dynamics Using Patient-Derived Xenografts Reveals Precision Medicine Strategies for Triple-Negative Breast Cancer.

Shea A, Eyal-Lubling Y, Guerrero-Romero D, Manzano Garcia R, Greenwood W, OReilly M Cancer Res. 2024; 85(3):567-584.

PMID: 39514406 PMC: 7617242. DOI: 10.1158/0008-5472.CAN-24-1703.


The roles of patient-derived xenograft models and artificial intelligence toward precision medicine.

Janitri V, Aruljothi K, Ravi Mythili V, Singh S, Prasher P, Gupta G MedComm (2020). 2024; 5(10):e745.

PMID: 39329017 PMC: 11424683. DOI: 10.1002/mco2.745.


References
1.
Kamal M, Shaaban A, Zhang L, Walker C, Gray S, Thakker N . Loss of CSMD1 expression is associated with high tumour grade and poor survival in invasive ductal breast carcinoma. Breast Cancer Res Treat. 2009; 121(3):555-63. DOI: 10.1007/s10549-009-0500-4. View

2.
Ng P, Henikoff S . SIFT: Predicting amino acid changes that affect protein function. Nucleic Acids Res. 2003; 31(13):3812-4. PMC: 168916. DOI: 10.1093/nar/gkg509. View

3.
Citron M, Berry D, Cirrincione C, Hudis C, Winer E, Gradishar W . Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and.... J Clin Oncol. 2003; 21(8):1431-9. DOI: 10.1200/JCO.2003.09.081. View

4.
Sjoblom T, Jones S, Wood L, Parsons D, Lin J, Barber T . The consensus coding sequences of human breast and colorectal cancers. Science. 2006; 314(5797):268-74. DOI: 10.1126/science.1133427. View

5.
Chan S, Lim C, Guo K, Peng Ng C, Lee I, Hunziker W . A role for TAZ in migration, invasion, and tumorigenesis of breast cancer cells. Cancer Res. 2008; 68(8):2592-8. DOI: 10.1158/0008-5472.CAN-07-2696. View